ProCE Banner Activity

Multidisciplinary Perspectives Informing Optimal Treatment of RET-Altered Lung and Thyroid Cancer

Multimedia
In this engaging on-demand webcast of a live CCO webinar, learn how experts interpret the latest data on RET inhibitors and how to integrate them into your clinical practice for optimal treatment of patients with RET-altered NSCLC or thyroid cancer.

Released: April 08, 2021

Expiration: April 07, 2022

Share

Faculty

Marcia Brose

Marcia Brose, MD, PhD, FASCO

Professor
Department of Medical Oncology
Sidney Kimmel Medical College
Thomas Jefferson University
Director, Sidney Kimmel Cancer Center
Vice Chair, Medical Oncology
Sidney Kimmel Medical College
Jefferson Northeast
Philadelphia, Pennsylvania

Karen L. Reckamp

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Laura J. Tafe

Laura J. Tafe, MD

Associate Professor of Pathology and Laboratory Medicine
Associate Director, Laboratory for Clinical Genomics and Advanced Technology (CGAT)
Director, Molecular Oncology
Department of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon, New Hampshire

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Learning Objectives

  • Evaluate the clinical utility of RET as a predictive biomarker for targeted therapy in NSCLC and thyroid cancer
  • Apply current recommendations to identify patients who should receive testing, provide effective counseling, and tailor biomarker testing options to the individual patient’s needs
  • Summarize ongoing research regarding the utility of selective RET inhibitors in patients with RET fusion–positive NSCLC, RET-mutant MTC, and RET fusion–positive thyroid cancer
  • Compare and contrast the different methodologies and assays for identifying RET alterations
  • Identify patients with RET-altered tumors who are candidates for ongoing clinical trials
  • Develop a proactive management plan for adverse events associated with therapies used to treat RET fusion–positive NSCLC, RET-mutant MTC, and RET fusion–positive thyroid cancer

Faculty Disclosure

Primary Author

Marcia Brose, MD, PhD, FASCO

Professor
Department of Medical Oncology
Sidney Kimmel Medical College
Thomas Jefferson University
Director, Sidney Kimmel Cancer Center
Vice Chair, Medical Oncology
Sidney Kimmel Medical College
Jefferson Northeast
Philadelphia, Pennsylvania

Marcia S. Brose, MD, PhD, has disclosed that she has received consulting fees and funds for research support from Bayer, Eisai, Exelixis, Lilly, and Loxo Oncology.

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Karen L. Reckamp, MD, MS, has disclosed that she has received consulting fees from AstraZeneca, Boehringer Ingelheim, Calithera, Genentech, Guardant, Precision Health, and Tesaro and funds for research support paid to her prior institution from AbbVie, Acea, Adaptimmune, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Guardant, Janssen, Loxo Oncology, Molecular Partners, Seattle Genetics, Spectrum, Takeda, Xcovery, and Zeno.

Laura J. Tafe, MD

Associate Professor of Pathology and Laboratory Medicine
Associate Director, Laboratory for Clinical Genomics and Advanced Technology (CGAT)
Director, Molecular Oncology
Department of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon, New Hampshire

Laura J. Tafe, MD, has disclosed that she has ownership interest GlaxoSmithKline.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.